Profluent, an AI-first protein design company, on Tuesday announced a multi-program partnership with Eli Lilly and Company worth up ?to $2.25 billion to develop AI-designed enzymes for genetic medicines.
The deal includes an upfront payment, along with potential development and commercial milestone payments and tiered royalties on net sales.
Profluent aid the collaboration aims to develop more precise and scalable DNA-editing tools by combining its AI protein design models with Lilly's expertise in genetic medicines. Profluent will design recombinases for specific genetic targets, while Lilly will have exclusive rights to develop and commercialize selected candidates.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.